Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Related REGN
UPDATE: Regeneron, Sanofi Report Commencement of Phase 3 Study Of Dupilumab In Patients With AD
TGIF As Markets Rally; S&P 500 Posts Longest Weekly Loss Streak Since 2011
Related SNY
NASDAQ Dips 1.5%; HB Fuller Shares Decline On Downbeat Results
Markets Tumble; Scholastic Posts Wider Fiscal-First Quarter Loss
Allergan Reportedly Seeks Alternate Suitor (Fox Business)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional